Remsima turned over in market share against original medicine for first time as biosimilar

Remsima and Truxima are raising its share in the European market.

According to Celltrion Healthcare, ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease, and ‘Truxima(generic name: rituximab),’ a biosimilar for the treatment of hematologic malignancies, reportedly recorded high market shares in Europe in the 4^th quarter of the last year.

Particularly, ‘Re...